
Voyager Therapeutics (VYGR) Stock Forecast & Price Target
Voyager Therapeutics (VYGR) Analyst Ratings
Bulls say
Voyager Therapeutics is positioned favorably due to its innovative TRACER platform, which is expected to generate revenue streams from collaborations that are advancing to clinical trials in the 2030s. The company's data on VY1706, demonstrating a significant reduction in tau messenger RNA and protein in non-human primates, underscores the potential for durable efficacy with lower liver exposure compared to existing AAV9 therapies. Additionally, recent preclinical studies highlight the NeuroShuttle's ability to maintain central nervous system exposure for an extended duration, suggesting both enhanced therapeutic durability and safety advantages, thereby enhancing the optimistic outlook for Voyager's future growth in the gene therapy market.
Bears say
Voyager Therapeutics has faced significant financial challenges, characterized by a high burn rate and limited cash reserves, which could hinder its ability to fund ongoing research and development activities necessary for advancing its gene therapy programs. Additionally, the company's pipeline, despite its innovative approach to treating severe neurological diseases, has encountered setbacks in clinical trials, raising concerns about the viability and market potential of its AAV-based gene therapies. Furthermore, uncertainties regarding regulatory approvals and the competitive landscape in the gene therapy sector add further risk to Voyager Therapeutics's financial outlook, contributing to a negative assessment of its overall stock performance.
This aggregate rating is based on analysts' research of Voyager Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Voyager Therapeutics (VYGR) Analyst Forecast & Price Prediction
Start investing in Voyager Therapeutics (VYGR)
Order type
Buy in
Order amount
Est. shares
0 shares